Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
Interventions: BIOLOGICAL: HER-2/neu peptide vaccine|PROCEDURE: leukapheresis|BIOLOGICAL: ex vivo-expanded HER2-specific T cells|DRUG: cyclophosphamide|BIOLOGICAL: sargramostim|OTHER: laboratory biomarker analysis
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)